Shop CJC-1295

Research tracker · References

CJC-1295 references and source documents

Every figure on this site resolves to one of the studies below. Each carries its PMID or DOI so the original record can be checked directly.

Back to the researchDAC vs no-DAC

How to read this list

These CJC-1295 references are the source record behind every quantitative claim on the site. The core human pharmacokinetic findings come from Teichman 2006 [1] and Ionescu/Frohman 2006 [3]; the foundational albumin-bioconjugate identification is Jette 2005 [2]; the once-daily growth-normalization result is Alba 2006 [7]. The remaining entries cover the proteomic fingerprint, the GHRH/sleep link, supporting ipamorelin and tesamorelin pharmacology, the IGF-1/cancer epidemiology, and recent reviews of the GHRH-analog class. PMIDs link to PubMed; DOIs resolve to the publisher of record. Where the published record disagrees on a detail — for example the exact molecular formula across chemical registries — that is a property of the sources, not an omission here.

The human CJC-1295 record

The direct human evidence for CJC-1295 is small and worth naming individually. Teichman 2006 established the dose-dependent multi-day GH/IGF-1 kinetics and the 5.8-8.1 day half-life in healthy adults [1]. Ionescu and Frohman 2006 showed that pulsatile GH secretion persists under continuous stimulation — the preserved-rhythm finding [3]. Sackmann-Sala 2009 added a serum-proteome fingerprint that tracked with IGF-1 [5]. These early-phase studies are the entirety of the controlled human pharmacokinetic record; there are no large efficacy or long-term safety trials in healthy adults, and a Phase 2 program in HIV-associated visceral obesity (NCT00267527) was discontinued.

Preclinical, class, and context studies

The animal and mechanistic backbone comes from Jette 2005, which identified CJC-1295 as the long-lasting albumin-bioconjugate GRF analog and reported the 4-fold GH AUC in rats [2], and Alba 2006, which normalized growth in the GHRH-knockout mouse on a once-daily schedule [7]. Class context comes from the GHRH/sleep work of Steiger 1992 [6], the ipamorelin pharmacology of Raun 1998 [4] and supporting PK-PD and bone studies [8][9], the tesamorelin trial record [12][13], the IGF-1/cancer epidemiology of Renehan 2004 [14], and recent reviews and methods spanning the GHRH-analog class and its anti-doping detection [10][11].

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Steiger A, Guldner J, Hemmeter U, et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in normal men. Neuroendocrinology. 1992;56(4):566-573. ↗
  7. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  8. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. ↗
  9. Svensson J, Lall S, Dickson SL, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001;11(Suppl A):S64-S65 (and related work, Bone 2000). ↗
  10. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗
  11. Neuroendocrine circuit for sleep-dependent growth hormone release. Cell. 2025. ↗
  12. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor analog (tesamorelin, TH9507) in HIV-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2010 (and related Phase 3 reports). ↗
  13. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin. Obes Res Clin Pract. 2026. ↗
  14. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗